Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Average Price Target from Analysts
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) has been assigned an average rating of “Hold” from the nine research firms that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) has been assigned an average rating of “Hold” from the nine research firms that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price […]
